DOCSLIB.ORG

Should Protease Inhibitors Be Used for COVID-19?

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

MOH-ACE COVID-19 RAPID REVIEW Updated 14 April 2020. First published 26 March 2020. Should protease inhibitors be used for COVID-19? This write-up summarises a rapid evidence review of protease inhibitors for treating COVID-19. The information may be revised as new evidence emerges. Background Protease inhibitors developed to treat HIV infection, have previously been trialed as a treatment for patients with Severe Acute Respiratory Syndrome (SARS-CoV); however, their clinical efficacy was inconclusive.1 As SARS-CoV and COVID-19 both belong to the Coronavirus family, protease inhibitors are currently being studied as a potential antiviral treatment for COVID-19 infection. Most ongoing trials are focusing on lopinavir/ritonavir (brand names: Kaletra, Aluvia), following reports of its efficacy in a patient with COVID-19 in South Korea.2 Clinical evidence A literature search of protease inhibitors used for treating COVID-19 was conducted on 13 April 2020.† Twenty-six clinical trials identified are currently ongoing, with results pending (Table 1). Only one clinical trial (LOTUS China) by Cao et al. and one case series by Chen et al. has published results to date. Table 1: List of ongoing trials investigating protease inhibitors for treating COVID-19 Study identifier Study Intervention Comparator(s) Date of primary Design completion LOTUS China trial, 3 SC*, OL, Lopinavir/ritonavir Standard of care 3 February 2020 ChiCTR2000029308 phIV, RCT NCT04291729 4 SC*, OL, Danoprevir and ritonavir with or NA March 2020 phIV, NRCT without interferon atomisation NCT04307693 5 MC, OL, phII, Lopinavir/ritonavir Hydroxychloroquine May 2020 RCT sulphate NCT04286503 6 MC, OL, Carrimycin Lopinavir/ritonavir February 2021 phIV, RCT Arbidol Chloroquine phosphate NCT04255017 7 SC*, SB, Lopinavir/ritonavir Abidol hydrochloride June 2020 phIV, RCT Oseltamivir NCT04295551 8 MC, OL, RCT Lopinavir/ritonavir Lopinavir/ritonavir with July 2020 Xiyanping injection NCT04303299 9 MC, OL, Mild COVID-19 Standard of care October 2020 phIII, RCT Oseltamivir and chloroquine Lopinavir/ritonavir with favipiravir Lopinavir/ritonavir with oseltamivir Moderate to severe COVID-19 Lopinavir/ritonavir with oseltamivir Lopinavir/ritonavir with favipiravir Darunavir/ritonavir with oseltamivir with chloroquine Darunavir/ritonavir with favipiravir with chloroquine NCT04261907 10 MC, OL, RCT ASC09 with ritonavir Lopinavir/ritonavir May 2020 NCT04315948 11 MC, OL, RCT Remdesivir Standard of care March 2023 Lopinavir/ritonavir Lopinavir/ritonavir with interferon β-1a † The literature search covered antiretroviral HIV-1 protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir and tipranavir); and hepatitis C virus NS3/4A protease inhibitors (asunaprevir, boceprevir, grazoprevir, glecaprevir, paritaprevir, simeprevir, telaprevir and danoprevir). Page 1 of 5 MOH-ACE COVID-19 RAPID REVIEW Updated 14 April 2020. First published 26 March 2020. NCT04275388 12 MC, OL, RCT Xiyanping injection with Lopinavir/ritonavir and May 2020 lopinavir/ritonavir and interferon-α interferon-α nebulisation nebulisation NCT04252274 13 SC*, OL, Darunavir and cobicistat Standard of care August 2020 phIII, RCT NCT04251871 14 SC*, OL, Traditional Chinese Medicines Lopinavir/ritonavir and January 2021 RCT granules, lopinavir/ritonavir and interferon-α nebulisation interferon-α nebulisation NCT04304053 15 MC, OL, Chloroquine, darunavir and Standard of care July 2020 phIII, CRCT cobicistat NCT04276688 16 SC*, OL, phII, Lopinavir/ritonavir, ribavirin and Lopinavir/ritonavir January 2022 RCT interferon β-1b NCT02735707 MC, OL, Lopinavir/ritonavir Standard of care December 2021 2015-002340-14 phIV, ARCT Hydroxychloroquine and REMAP-CAP: lopinavir/ritonavir COVID-19 Antiviral Hydroxychloroquine 17, Therapy Domain Levofloxacin 18 Hydrocortisone Ceftriaxone Azithromycin Clarithromycin Erythromycin Amoxicillin/clavulanate Piperacillin/tazobactam Roxithromycin Ceftaroline fosamil Moxifloxacin Oseltamivir Anakinra Interferon beta-1a ASID Australia New NA Lopinavir/ritonavir Standard of care NA South Wales trial Lopinavir/ritonavir and hydroxychloroquine Hydroxychloroquine ISRCTN83971151 NA Remdesivir Standard of care March 2021 SOLIDARITY 19, 20 Lopinavir/ritonavir Lopinavir/ritonavir and interferon β-1a Chloroquine or hydroxychloroquine NCT04330690 MC, OL, Lopinavir/ritonavir Standard of care March 2022 SOLIDARITY- phIII, ARCT Canada 21 2020-001366-11 MC, OL, Remdesivir Standard of care NA SOLIDARITY- Spain phIII, ARCT Chloroquine 22 Hydroxychloroquine sulfate Lopinavir/ritonavir Interferon-beta-1a NCT04321993 23 OL, phII, Lopinavir/ritonavir Standard of care February 2021 NRCT Hydroxychloroquine sulphate Baricitinib Sarilumab NCT04321174 24 MC, OL, Lopinavir/ritonavir Patient cohort: standard March 2021 phIII, RCT of care Prevention cohort: no intervention 2020-000936-23 25 MC, OL, Lopinavir/ritonavir Standard of care March 2023 phIII, ARCT Interferon beta-1a Remdesivir Hydroxychloroquine 2020-001113-21 26 MC, OL, Lopinavir/ritonavir Standard of care NA RECOVERY phIII, ARCT Dexamethasone Azithromycin Hydroxychloroquine NCT04328285 27 MC, DB, Hydroxychloroquine Placebo November 2020 phIII, RCT Lopinavir/ritonavir NCT04331470 28 SC, OL, Levamisole and Hydroxychoroquine and April 2020 phII/III, RCT budesonide/formoterol inhaler lopinavir/ritonavir and hydroxychoroquine and lopinavir/ritonavir NCT04328012 29 SC, DB, Lopinavir/ritonavir Placebo January 2021 phII/III, ARCT Hydroxychloroquine sulphate Page 2 of 5 MOH-ACE COVID-19 RAPID REVIEW Updated 14 April 2020. First published 26 March 2020. Losartan 2020-001188-96 30 MC, DB, Lopinavir/ritonavir Placebo NA phIII, RCT Hydroxychloroquine 2020-001031-27 31 SC, OL, phIII, Darunavir/cobicistat Patient cohort: standard NA CRCT Hydroxychloroquine of care Prevention cohort: no intervention Abbreviations: DB, double blind; SB, single blind; MC, multicenter; OL, open label, phII, phase II; phIII, phase III; phIV, phase IV; RCT, randomised controlled trial; CRCT, cluster randomised controlled trial; ARCT, adaptive randomised controlled trial; SC, single centre; NA, not available; † None of the listed trials include Singapore as a study site. * China The World Health Organization (WHO) has announced that it will be conducting a large, global trial (SOLIDARITY) on the four most promising therapies identified to date to treat COVID-19, including lopinavir/ritonavir. Over 70 countries are currently included in the trial, with more countries likely to be included over time. The date of primary completion is March 2021, with findings reported by December 2021.19, 20 Lopinavir/ritonavir The LOTUS China trial3 conducted in 199 patients with severe COVID-19 reported that there was no significant difference in time to clinical improvement between patients who received lopinavir/ritonavir in addition to standard care versus standard of care alone (median 16 days). There was also no significant difference in mortality between the two groups although the 28-day mortality rate was numerically lower with lopinavir/ritonavir compared with standard of care (19.2% vs 25%). Standard of care comprised supplemental oxygen, ventilation, antibiotic agents, vasopressor support, renal- replacement therapy and extracorporeal membrane oxygenation (ECMO) as necessary. The proportion of patients who experienced grade 3 or 4 adverse events were comparable between the two treatment groups (lopinavir/ritonavir: 39%, standard of care: 42%). Nearly 14% of patients receiving lopinavir/ritonavir could not complete the full 14-day course due to gastrointestinal adverse events. The authors noted that the enrolled patients were likely to be more ill than typical patients which may have affected the results. A post-hoc analysis concluded that patients who received lopinavir/ritonavir within 12 days of symptom onset may experience faster clinical recovery and lower mortality (HR 1.25; 95%CI 1.17 to 2.05) compared to later treatment, but this finding was highly uncertain and required further research.3 Danoprevir/ritonavir A case series of 11 patients with moderate COVID-19 infection who received danoprevir/ritonavir with or without alpha-interferon nebulisation was published online by Chen et al.32 The article, which has not been peer reviewed, reported that all 11 patients recovered following 4 to 12 days of treatment with danoprevir/ritonavir. Viral nucleic acids in nasal swabs turned negative at a median of 2 days (range 1 to 8 days) and the absorption of acute exudative lesions occurred at a median of 3 days (range 2 to 4 days) after the initiation of danoprevir/ritonavir treatment. Due to the small sample size, lack of control subjects and possible selection bias, the significance of the reported outcomes is unclear and not considered generalisable to all patients. Larger randomised controlled trials are required to determine the clinical benefit of danoprevir/ritonavir for treating COVID-19. Recommendations from professional bodies WHO, US Centers for Disease Control and Prevention (CDC), European Medicines Agency, NHS (UK), Taiwan Centers for Disease Control, Singapore National Centre for Infectious Diseases (NCID) and governments in Australia, Canada, New Zealand and South Korea have reported that there is currently no approved targeted treatment for COVID-19 and symptom management is currently the best available option.33, 34, 35, 36, 37, 38, 39, 40, 41, 42 Page 3 of 5
Recommended publications
  • Drug Repurposing for Identification of Potential Inhibitors Against SARS-Cov-2 Spike Receptor-Binding Domain: an in Silico Approach

    Drug Repurposing for Identification of Potential Inhibitors Against SARS-Cov-2 Spike Receptor-Binding Domain: an in Silico Approach

    Indian J Med Res 153, January & February 2021, pp 132-143 Quick Response Code: DOI: 10.4103/ijmr.IJMR_1132_20 Drug repurposing for identification of potential inhibitors against SARS-CoV-2 spike receptor-binding domain: An in silico approach Santosh Kumar Behera1, Namita Mahapatra1, Chandra Sekhar Tripathy1 & Sanghamitra Pati2 1Health Informatics Centre, 2ICMR-Regional Medical Research Centre, Bhubaneswar, Odisha, India Received April 10, 2020 Background & objectives: The world is currently under the threat of coronavirus disease 2019 (COVID-19) infection, caused by SARS-CoV-2. The objective of the present investigation was to repurpose the drugs with potential antiviral activity against receptor-binding domain (RBD) of SARS-CoV-2 spike (S) protein among 56 commercially available drugs. Therefore, an integrative computational approach, using molecular docking, quantum chemical calculation and molecular dynamics, was performed to unzip the effective drug-target interactions between RBD and 56 commercially available drugs. Methods: The present in silico approach was based on information of drugs and experimentally derived crystal structure of RBD of SARS-CoV-2 S protein. Molecular docking analysis was performed for RBD against all 56 reported drugs using AutoDock 4.2 tool to screen the drugs with better potential antiviral activity which were further analysed by other computational tools for repurposing potential drug or drugs for COVID-19 therapeutics. Results: Drugs such as chalcone, grazoprevir, enzaplatovir, dolutegravir, daclatasvir, tideglusib, presatovir, remdesivir and simeprevir were predicted to be potentially effective antiviral drugs against RBD and could have good COVID-19 therapeutic efficacy. Simeprevir displayed the highest binding affinity and reactivity against RBD with the values of −8.52 kcal/mol (binding energy) and 9.254 kcal/mol (band energy gap) among all the 56 drugs under investigation.
  • OLYSIO (Simeprevir) Capsules, for Oral Use Ribavirin May Cause Birth Defects and Fetal Death and Animal Studies Initial U.S

    OLYSIO (Simeprevir) Capsules, for Oral Use Ribavirin May Cause Birth Defects and Fetal Death and Animal Studies Initial U.S

    • Because ribavirin may cause birth defects and fetal death, OLYSIO in HIGHLIGHTS OF PRESCRIBING INFORMATION combination with peginterferon alfa and ribavirin is contraindicated in These highlights do not include all the information needed to use pregnant women and in men whose female partners are pregnant. (4) OLYSIOTM safely and effectively. See full prescribing information for OLYSIO. ------------------------WARNINGS AND PRECAUTIONS----------------------­ • Embryofetal Toxicity (Use with Ribavirin and Peginterferon Alfa): OLYSIO (simeprevir) capsules, for oral use Ribavirin may cause birth defects and fetal death and animal studies Initial U.S. Approval – 2013 have shown interferons have abortifacient effects; avoid pregnancy in female patients and female partners of male patients. Patients must have ----------------------------INDICATIONS AND USAGE---------------------------­ a negative pregnancy test prior to initiating therapy, use at least OLYSIO is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated for two effective methods of contraception during treatment, and undergo the treatment of chronic hepatitis C (CHC) infection as a component of a monthly pregnancy tests. (5.1) combination antiviral treatment regimen. (1) • Photosensitivity: Serious photosensitivity reactions have been observed • OLYSIO efficacy has been established in combination with during combination therapy with OLYSIO, peginterferon alfa and peginterferon alfa and ribavirin in HCV genotype 1 infected subjects ribavirin. Use sun protection measures and limit sun exposure. Consider with compensated liver disease (including cirrhosis). (1, 14) discontinuation if a photosensitivity reaction occurs. (5.2) • OLYSIO must not be used as monotherapy. (1) • Rash: Rash has been observed during combination therapy with • Screening patients with HCV genotype 1a infection for the presence of OLYSIO, peginterferon alfa and ribavirin.
  • Pharmaceutical Targeting the Envelope Protein of SARS-Cov-2: the Screening for Inhibitors in Approved Drugs

    Pharmaceutical Targeting the Envelope Protein of SARS-Cov-2: the Screening for Inhibitors in Approved Drugs

    Pharmaceutical Targeting the Envelope Protein of SARS-CoV-2: the Screening for Inhibitors in Approved Drugs Anatoly Chernyshev XR Pharmaceuticals Ltd., Cambridge, New Zealand email: [email protected] Abstract An essential overview of the biological role of coronavirus viroporin (envelope protein) is given, together with the effect of its known inhibitors on the life cycle of coronavirus. A docking study is conducted using a set of known drugs approved worldwide (ca. 6000 compounds) on a structure of the SARS-CoV-2 viroporin modelled from the published NMR-resolved structures. The screening has identified 36 promising drugs currently on the market, which could be proposed for pre-clinical trials. Introduction Viral ion channels (viroporins) are known since at least 1992, when the M2 channel of influenza A virus has been discovered. These ion channels exist in a form of homotetra- (e.g. the M2 channel) or homopentamers (e.g. coronavirus E channel); each subunit is 50–120 aminoacids long and has at least one transmembrane domain (TMD). The pore formed by the transmembrane domains of the oligomer acts as an ion channel. It is speculated that viroporins initiate a leakage in host cell membranes, which alters the tans-membrane potential and serves as a marker of viral infection [1]. SARS coronaviruses were found to have at least three types of ion channels: E and 8a (both with single TMD, forming pentameric assemblies), and 3a with three TMD [2, 3]. Both proteins E and 3a possess PDZ domain- binding motif (PBM). In the protein E it is the last four aminoacids in the C-terminus (DLLV, Table 1).
  • Informatorium of COVID-19 Drugs in Indonesia" Has Been Compiled and Can Be Published Amidst the COVID-19 Outbreak in Indonesia

    Informatorium of COVID-19 Drugs in Indonesia" Has Been Compiled and Can Be Published Amidst the COVID-19 Outbreak in Indonesia

    THE INDONESIAN FOOD AND DRUG AUTHORITY INFORMATORIUM OF COVID-19 DRUGS IN INDONESIA THE INDONESIAN FOOD AND DRUG AUTHORITY MARCH 2020 1 INFORMATORIUM OF COVID-19 DRUGS IN INDONESIA THE INDONESIAN FOOD AND DRUG AUTHORITY ISBN 978-602-415-009-9 First Edition March 2020 COPYRIGHT PROTECTED BY LAW Reproduction of this book in part or whole, in any form and by any means, mechanically or electronically, including photocopies, records, and others without written permission from the publisher. This informatorium is based on information up to the time of publication and is subject to change if there is the latest data/information 2 3 FOREWORD Our praise and gratitude for the presence of God Almighty for His blessings and gifts, "The Informatorium of COVID-19 Drugs in Indonesia" has been compiled and can be published amidst the COVID-19 outbreak in Indonesia. As we know, the infections due to Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) began to plague in December 2019 in Wuhan City, Hubei Province, People's Republic of China. The disease was caused by SARS-CoV-2 infection which was later known as Coronavirus Disease 2019 (COVID-19) which in early 2020 began to spread to several countries and eventually spread to almost all countries in the world. On March 11, 2020, WHO announced COVID-19 as a global pandemic. In Indonesia, the first case was officially announced on March 2, 2020. Considering that the spread of COVID-19 has been widespread and has an impact on social, economic, defense, and public welfare aspects in Indonesia, the President of the Republic of Indonesia established the Task Force for the Acceleration of COVID- 19 Handling aiming to increase readiness and ability to prevent, detect and respond to COVID-19.
  • Estonian Statistics on Medicines 2016 1/41

    Estonian Statistics on Medicines 2016 1/41

    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
  • Antiviral Effects of Simeprevir on Multiple Viruses

    Antiviral Effects of Simeprevir on Multiple Viruses

    Antiviral Research 172 (2019) 104607 Contents lists available at ScienceDirect Antiviral Research journal homepage: www.elsevier.com/locate/antiviral Antiviral effects of simeprevir on multiple viruses T Zheng Lia,b,1, Fujia Yaoa,b,1, Guang Xuea,b,1, Yongfen Xua,b, Junling Niua,b, Mengmeng Cuia,b, ∗ Hongbin Wanga,b, Shuxian Wua,b, Ailing Lua,b,c, Jin Zhonga,b, Guangxun Menga,b, a CAS Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, 200031, China b University of Chinese Academy of Sciences, Beijing, 100039, China c Faculty of Medical Laboratory Science, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200025, China ARTICLE INFO ABSTRACT Keywords: Simeprevir was developed as a small molecular drug targeting the NS3/4A protease of hepatitis C virus (HCV). Simeprevir Unexpectedly, our current work discovered that Simeprevir effectively promoted the transcription of IFN-β and ZIKV ISG15, inhibited the infection of host cells by multiple viruses including Zika virus (ZIKV), Enterovirus A71 (EV- EV-A71 A71), as well as herpes simplex virus type 1 (HSV-1). However, the inhibitory effects of Simeprevir on ZIKV, EV- HSV-1 A71 and HSV-1 were independent from IFN-β and ISG15. This study thus demonstrates that the application of IFN-β Simeprevir can be extended to other viruses besides HCV. ISG15 Treatment of hepatitis C virus (HCV) infection has been significantly kilobase, positive-sense RNA genome (Sirohi and Kuhn, 2017). ZIKV improved with the development of direct-acting antiviral agents infection causes neurological complications, microcephaly in fetus, and (DAAs).
  • Usage of Antivirals and the Occurrence of Antiviral Resistance in Norway 2018

    Usage of Antivirals and the Occurrence of Antiviral Resistance in Norway 2018

    REPORT 2019 Usage of Antivirals and the Occurrence of Antiviral Resistance in Norway 2018 RAVN Resistensovervåking av virus i Norge Resistance against Antivirals in Norway Usage of Antivirals and the Occurrence of Antiviral resistance in Norway 2018 RAVN Resistensovervåkning av virus i Norge Resistance against antivirals in Norway 2 Published by the Norwegian Institute of Public Health Division of Infection Control and Environmental Health Department for Infectious Disease registries October 2019 Title: Usage of Antivirals and the Occurrence of Antiviral Resistance in Norway 2018. RAVN Ordering: The report can be downloaded as a pdf at www.fhi.no Graphic design cover: Fete Typer ISBN nr: 978-82-8406-032-3 Emneord (MeSH): Antiviral resistance Any usage of data from this report should include a specific reference to RAVN. Suggested citation: RAVN. Usage of Antivirals and the Occurrence of Antiviral Resistance in Norway 2018. Norwegian Institute of Public Health, Oslo 2019 Resistance against antivirals in Norway • Norwegian Institute of Public Health 3 Table of contents Introduction _________________________________________________________________________ 4 Contributors and participants __________________________________________________________ 5 Sammendrag ________________________________________________________________________ 6 Summary ___________________________________________________________________________ 8 1 Antivirals and development of drug resistance ______________________________________ 10 2 The usage of antivirals in Norway
  • Hepatitis C Virus Drugs Simeprevir and Grazoprevir Synergize With

    Hepatitis C Virus Drugs Simeprevir and Grazoprevir Synergize With

    bioRxiv preprint doi: https://doi.org/10.1101/2020.12.13.422511; this version posted December 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Hepatitis C Virus Drugs Simeprevir and Grazoprevir Synergize with 2 Remdesivir to Suppress SARS-CoV-2 Replication in Cell Culture 3 Khushboo Bafna1,#, Kris White2,#, Balasubramanian Harish3, Romel Rosales2, 4 Theresa A. Ramelot1, Thomas B. Acton1, Elena Moreno2, Thomas Kehrer2, 5 Lisa Miorin2, Catherine A. Royer3, Adolfo García-Sastre2,4,5,*, 6 Robert M. Krug6,*, and Gaetano T. Montelione1,* 7 1Department of Chemistry and Chemical Biology, and Center for Biotechnology and 8 Interdisciplinary Sciences, Rensselaer Polytechnic Institute, Troy, New York, 12180 9 USA. 10 11 2Department of Microbiology, and Global Health and Emerging Pathogens Institute, 12 Icahn School of Medicine at Mount Sinai, New York, NY10029, USA. 13 14 3Department of Biology, and Center for Biotechnology and Interdisciplinary Sciences, 15 Rensselaer Polytechnic Institute, Troy, New York, 12180 USA. 16 17 4Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at 18 Mount Sinai, New York, NY 10029, USA. 19 20 5The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 21 10029, USA 22 23 6Department of Molecular Biosciences, John Ring LaMontagne Center for Infectious 24 Disease, Institute for Cellular and Molecular Biology, University of Texas at Austin, 25
  • Simeprevir Potently Suppresses SARS-Cov-2 Replication and Synergizes with Remdesivir

    Simeprevir Potently Suppresses SARS-Cov-2 Replication and Synergizes with Remdesivir

    bioRxiv preprint doi: https://doi.org/10.1101/2020.05.26.116020; this version posted September 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Simeprevir potently suppresses SARS-CoV-2 replication and synergizes with remdesivir Authors Ho Sing Lo1,*, Kenrie Pui Yan Hui2,*, Hei-Ming Lai3-5,*, Khadija Shahed Khan1, Simranjeet Kaur6, Junzhe Huang4,5, Zhongqi Li4,5, Anthony K. N. Chan7, Hayley Hei-Yin Cheung8, Ka-Chun Ng2, John Chi Wang Ho2, Yu Wai Chen9, Bowen Ma1, Peter Man- Hin Cheung10, Donghyuk Shin11, Kaidao Wang12, Meng-Hsuan Lee13, Barbara Selisko14, Cecilia Eydoux14, Jean-Claude Guillemot14, Bruno Canard14, Kuen-Phon Wu13, Po-Huang Liang13, Ivan Dikic11, Zhong Zuo1, Francis K. L. Chan4,15, David S. C. Hui4,16, Vincent C. T. Mok4,17, Kam-Bo Wong8, Ho Ko3-5,17-19, Wei Shen Aik6, Michael Chi Wai Chan2,†, Wai-Lung Ng1,† Affiliations 1School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong 2School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong 3Department of Psychiatry, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong 4Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong 5Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong 6Department of Chemistry, Faculty of Science, Hong Kong Baptist University, Hong Kong 7Department
  • Simeprevir PK Fact Sheet Reviewed March 2016 Page 1 of 2 for Personal Use Only

    Simeprevir PK Fact Sheet Reviewed March 2016 Page 1 of 2 for Personal Use Only

    www.hep-druginteractions.org Simeprevir PK Fact Sheet Reviewed March 2016 Page 1 of 2 For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution. Details Generic Name Simeprevir Trade Name Olysio® Class NS3/4A protease inhibitor Molecular Weight 749.94 Structure Summary of Key Pharmacokinetic Parameters Linearity/non‐linearity Plasma Cmax and AUC increased more than dose proportional after multiple doses between 75 mg and 200 mg once daily, with accumulation occurring following repeated dosing. Steady State Steady‐state was reached after 7 days of once daily dosing. Plasma Half life 41 h (200 mg once daily, multiple dose in HCV infected patients) [cf 10‐13 h in HCV‐uninfected subjects] Cmax Not determined Cmin 1936 ± 2640 ng/ml (mean ± sd, HCV subjects) AUC 57,469 ± 63571 ng.h/ml (mean ± sd, HCV subjects) (Pooled population PK estimates of exposure after 150 mg once daily for 12 weeks in genotype 1 patients: White 55,619 ng.h/ml; Black 47,986 ng.h/ml; Asian 196,750 ng.h/ml)1. Simeprevir AUC was about 2‐ to 3‐fold higher in HCV infected patients compared to that observed in healthy subjects. 1 Interindividual Variation 87% for AUC0‐24 in Phase I study Bioavailability 62% Absorption Compared to intake without food, administration of simeprevir with food to healthy subjects increased the AUC by 61% after a high‐fat, high‐caloric (928 kcal) and 69% after a normal caloric (533 kcal) breakfast, and delayed the absorption by 1 hour and 1.5 hours, respectively.
  • Curing Chronic Hepatitis C: a Cost Comparison of the Combination Simeprevir Plus Sofosbuvir Vs

    Curing Chronic Hepatitis C: a Cost Comparison of the Combination Simeprevir Plus Sofosbuvir Vs

    366 Langness JA, et al. , 2017; 16 (3): 366-374 ORIGINAL ARTICLE May-June, Vol. 16 No. 3, 2017: 366-374 The Official Journal of the Mexican Association of Hepatology, the Latin-American Association for Study of the Liver and the Canadian Association for the Study of the Liver Curing Chronic Hepatitis C: A Cost Comparison of the Combination Simeprevir Plus Sofosbuvir vs. Protease-Inhibitor-Based Triple Therapy Jacob A. Langness,*,† David Tabano,† Amanda Wieland,‡ Sarah Tise,‡ Lindsay Pratt,‡ Lauren Ayres Harrington,§ Sonia Lin,* Vahram Ghuschcyan,†,|| Kavita V. Nair,† Gregory T. Everson§ * Department of Pharmacy, University Of Colorado Hospital, Aurora, CO, USA. † Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. ‡ University of Colorado Denver, Department of Medicine, Division of Gastroenterology and Hepatology, Aurora, CO, USA. § University of Colorado Denver, School of Medicine, Aurora, CO, USA. || American University of Armenia, Yerevan, Armenia. ABSTRACT Introduction. Interferon-free, multi-direct acting antiviral (DAA) therapy for chronic hepatitis C virus (HCV) infection is highly effec- tive and well tolerated, but costly. To gain perspective on the evolving economics of HCV therapy, we compared the cost per cure of a multi-DAA regimen with the prior standard of triple therapy. Material and methods. Patients infected with HCV genotype 1 who were treated through the University of Colorado Hepatology Clinic between May 2011 and December 2014 comprised the study population. The multi-DAA regimen of simeprevir plus sofosbuvir (SMV/SOF) was compared to the triple therapy regimen consisting of peginterferon and ribavirin, with either boceprevir or telaprevir (TT).
  • Olysio® (Simeprevir), Sovaldi® (Sofosbuvir), & Ribavirin Treatment Agreement

    Olysio® (Simeprevir), Sovaldi® (Sofosbuvir), & Ribavirin Treatment Agreement

    Olysio® (Simeprevir), Sovaldi® (Sofosbuvir), & Ribavirin Treatment Agreement Liver Disease & Hepatitis Program Providers: Brian McMahon, MD; Youssef Barbour, MD; Lisa Townshend-Bulson, FNP-C; Annette Hewitt, FNP-C; Prabhu Gounder, MD; Ellen Provost, DO; Timothy Thomas, MD; Stephen Livingston, MD Family Medicine Provider: _____________________________________________ If you are considering hepatitis C treatment, please read this treatment agreement carefully and be sure to ask any questions you may have before you sign the form. The American Association for the Study of Liver Diseases (AASLD)/Infectious Disease Society of America (IDSA) Guidelines for hepatitis C treatment recommends simeprevir, sofosbuvir, and weight-based ribavirin treatment in certain circumstances for genotype 1 hepatitis C after testing for NS5A and NS3 (Q80K) resistance associated variants (RAVs). Treatment with simeprevir, sofosbuvir, and ribavirin requires approximately 9 scheduled visits over 9 months. PREGNANCY & BREASTFEEDING WARNING Ribavirin can harm an unborn child or breastfeeding infant. A woman must not get pregnant and a man must not father a child while taking ribavirin or for 6 months after treatment. You must use 2 forms of birth control when you take ribavirin and for 6 months after your last dose. Acceptable Birth Control Methods (must use 2): Birth control pills or other hormone containing birth control Male or female condom Spermicides (creams, films, foams, gels, and/or suppositories) Diaphragm or cervical cap Intrauterine device (IUD), Today® vaginal sponge Unacceptable Birth Control Methods: Rhythm method or withdrawal HOW THE TREATMENT PROCESS WORKS You will have blood and urine tests. • These tests will include a pregnancy test for female patients of childbearing age. Urine pregnancy tests will be done monthly during clinic visits.